Entera Bio Ltd - Warrants (02/07/2023) Return on Equity

Entera Bio Ltd - Warrants (02/07/2023) (ENTXW) currently reports a ROE of 219.52%. That is above the Healthcare sector average of 22.01%. Use the charts on this page to explore Entera Bio Ltd - Warrants (02/07/2023)'s ROE history and peer comparisons.

Entera Bio Ltd - Warrants (02/07/2023)'s ROE of 219.52% is higher than the Healthcare sector average of 22.01%. That is roughly 897.4% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Entera Bio Ltd - Warrants (02/07/2023)'s current 219.52% should be judged against Healthcare norms (sector average: 22.01%) and against ENTXW's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 219.52%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.01%. From there, open related valuation or income-statement pages for Entera Bio Ltd - Warrants (02/07/2023), and consider following ENTXW for alerts when major investors trade the stock.

Entera Bio Ltd - Warrants (02/07/2023) is classified in the Healthcare sector. On ROE, it currently shows 219.52% versus a sector average near 22.01%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ENTXW with unrelated industries.